Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
US5741796A · kind A · utility
43Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 1996 |
| Grant date | Apr 21, 1998 |
| Priority date | — |
| Expiry date | Sep 26, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of the following general structure X-Y-Z-Aryl-A-B, for example, ##STR1## which inhibit osteoclast mediated bone resorption. Specifically, the compounds are useful for treating mammals suffering from a bone condition caused or mediated by increased bone resorption, who are in need of such therapy. The compounds may be administered in oral dosage forms such as tablets, capsules, e.g. sustained release capsules, powders, granules, and suspensions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.